Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3201 - An Open-Label Study on Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients with Advanced, Recurrent Small Cell Lung Cancer


09 Sep 2017


Poster display session


Isamu Okamoto


Annals of Oncology (2017) 28 (suppl_5): v539-v542. 10.1093/annonc/mdx386


I. Okamoto1, H. Udagawa2, S. Kanda3, T.H. Han4, I. Lakatos4, F. Zhang4, S. Okubo5, C. Scripture6, M. Takeda7, H. Akamatsu8, T. Tamura9

Author affiliations

  • 1 Research Institute For Disease Of The Chest, Graduate School Of Medical Sciences, Kyushu University Hospital, 812-8582 - Fukuoka/JP
  • 2 Department Of Thoracic Oncology, National Cancer Center Hospital East, Chiba/JP
  • 3 Department Of Thoracic Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 4 Clinical Development, AbbVie Stemcentrx LLC, South San Francisco/US
  • 5 Clinical Development, AbbVie Japan GK, Osaka/JP
  • 6 Clinical Development, AbbVie Stemcentrx LLC, 94080 - South San Francisco/US
  • 7 Department Of Medical Oncology, Kindai University Hospital, 589-8511 - Osaka/JP
  • 8 Third Department Of Internal Medicine, Wakayama Medical University Hospital, Wakayama/JP
  • 9 Thoracic Center, St. Luke's International Hospital, 104-8560 - Tokyo/JP


Abstract 3201


Small cell lung cancer (SCLC) is a chemoresponsive malignancy with high response rates in early lines of therapy, but will inevitably recur. For patients (pts) with progressive SCLC following treatment with at least two prior therapies, standard treatment has not been established. Rovalpituzumab tesirine (Rova-T™) is an antibody-drug conjugate that targets Delta-like protein 3 (DLL3), an atypical Notch receptor family ligand and a marker specific for tumor-initiating cells in SCLC and other neuroendocrine cancers. Rova-T is comprised of a humanized DLL3-specific IgG1 monoclonal antibody tethered to a toxic DNA cross-linking agent by a cleavable linker. Rova-T binds DLL3 on target-expressing cells, is internalized, and the toxin released to induce cell death. A Phase 1 study of Rova-T in SCLC demonstrated robust antitumor activity in DLL3-high pts and a manageable safety profile1. The safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of Rova-T has not been evaluated in Japanese SCLC pts, thus a study of Rova-T in this population is warranted.

Trial design

This is a Phase 1, multicenter, Japanese, open-label dose escalation study (NCT03086239). Primary objective: to assess safety and tolerability of Rova-T in Japanese pts with advanced, recurrent SCLC. Secondary objectives: to explore antitumor activity of Rova-T; to study PK and pharmacodynamics of Rova-T. Pt eligibility: histologically or cytologically confirmed advanced, recurrent SCLC with measurable disease and documented disease progression after at least 2 prior systemic regimens, including at least 1 platinum-based regimen; ECOG 0-1; no prior exposure to a pyrrolobenzodiazepine-based drug. A standard 3 + 3 dose escalation will be used with ≤ 18 pts enrolled (6/dose level x 3 levels) and ≤ 60 pts if expansion cohorts are executed (20/dose level x 3 levels). Pts will receive Rova-T 0.2, 0.3, or 0.4 mg/kg intravenously on Day 1 of each 6-week cycle x 2 doses and dexamethasone 8 mg orally twice daily on Day -1, Day 1, and Day 2 of each 6-week cycle. Dose escalation will proceed until a single maximum tolerated dose (MTD) is determined (not to exceed 0.4 mg/kg). 1. Rudin et al., Lancet Oncol, 2016.

Clinical trial identification


Legal entity responsible for the study

AbbVie Stemcentrx


AbbVie Stemcentrx


I. Okamoto, H. Udagawa, S. Kanda, M. Takeda, H. Akamatsu: Serves as an investigator for Abbvie Stemcentrx. T.H. Han, I. Lakatos, F. Zhang, C. Scripture: Employee of AbbVie Stemcentrx and may own AbbVie stock. S. Okubo: Employee of AbbVie and may own AbbVie stock. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.